Ionis Plans to Launch Clinical Trial This Year for ION582

Ionis Plans to Launch Clinical Trial This Year for ION582

291788

Ionis Plans to Launch Clinical Trial This Year for ION582

Ionis Pharmaceuticals intends to launch a clinical trial later this year to test ION582, a potential Angelman syndrome therapy.  The Phase 1/2a trial, designed to enroll up to 50 patients, is expected to start in the second half of 2021, Ionis wrote in a letter to the Angelman community, published on the website of the Foundation for Angelman Syndrome Therapeutics (FAST). “We are completing the necessary preclinical studies with our lead compound and we are confident…

You must be logged in to read/download the full post.